Home
Clinical Trials
Orca-T Expanded Access Progra...

Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies

Last Updated: 2026-01-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TEMPORARILY_NOT_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is not designed to test a hypothesis; rather, this study will provide patients with access to Orca-T if the commercial Orca-T product produced for them is deemed out of specification (OOS). Serious adverse events (SAEs) occurring during the safety reporting period (defined as the day the recipient receives the Orca-T HSPC drug product through day +365 after transplantation or until initiation of new anticancer therapy, whichever occurs sooner) will be reported.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

NCT06195891

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Myelodysplastic Syndrome

RECRUITING PHASE1

SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

NCT00798213

Leukemia, Myeloid, Acute Lymphoblastic Leukemia, Acute

TERMINATED PHASE2

Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

NCT06427330

Acute Lymphoid Leukemia

RECRUITING PHASE2

Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia

NCT06845592

Acute Myeloid Leukaemia (AML) Acute Lymphoblastic Leukemia ALL High Risk Leukaemia +1 more

RECRUITING NA

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

NCT00776503

Myelodysplastic Syndromes

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Malignancies Acute Myeloid Leukemia Acute Lymphoid Leukemia Myelodysplastic Syndrome Mixed Phenotype Acute Leukemia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Orca-T

Orca-T that does not meet commercial release specifications

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Recipients in this EAP must meet all of the following criteria:

1. Commercial Orca-T was prescribed to the patient by their treating physician.
2. The final manufactured Orca-T does not meet the commercial release specifications or is delivered past expiry.
3. The final manufactured Orca-T is acceptable per joint assessment by Orca Bio and the treating physician, taking into account Orca Bio's release criteria.
4. Remanufacturing (ie, repeat leukapheresis and manufacturing) is not clinically appropriate per the treating physician's assessment.
5. Recipient must be deemed medically fit and stable to receive Orca-T infusions per the treating physician's evaluation.

Exclusion Criteria

Recipients with any medical condition identified by the treating physician that may impact the safety or outcomes of the recipient in relation to treatment with Orca-T will not be eligible.

Eligible Sex

ALL

Accepts Healthy Volunteers